Clinical Trial: Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Brief Summary: To provide treatment opportunity to children and adolescent patients with hematologic malignancies by supplying the delayed marketed product and also to observe the efficacy and safety of rasburicase used in the treatment of hyperuricemia

Detailed Summary:
Sponsor: Sanofi

Current Primary Outcome: Response will be defined as achievement of normal uric acid levels (less than or = to 7.0mg/dL)

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Sanofi

Dates:
Date Received: November 21, 2007
Date Started: March 2003
Date Completion:
Last Updated: January 24, 2008
Last Verified: January 2008